Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01967602

Acronym

ARDS

Enrollment

Registered

2013-10-23

Start date

2011-10-31

Completion date

2015-04-30

Last updated

2013-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Multi-organ Failure

Keywords

Acute respiratory distress syndrome (ARDS), Extracorporeal membrane oxygenation (ECMO), biomarker

Brief summary

The goal of this project is to find a marker expression that the investigators can use to trace symptom progression and develop a more efficient therapy to enhance ARDS patient survival rate and better post-ICU life quality.

Detailed description

The investigators will first identify acute respiratory distress syndrome (ARDS) patients receiving ECMO support in ICU at National Taiwan University Hospital, and then collect blood, urine and bronchioalveolar lavage fluid (BALF) samples at different time points: before setting up ECMO, 2, 6, 12, 24, 72 hours,5 and 14 days after ECMO installment, time to wean ECMO and the day removing ECMO and leaving ICU. From the samples, the free radicals, cytokines (IL-1, IL-6, IL-8, IL-18,tumor necrosis factor-α, transforming growth factor-β), and inflammasome- related markers, immune cell responses and other biochemical markers would be measured. The novel biomarkers to predict the outcome of the patient will be identified.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. \>18 years old 2. ARDS, needing ECMO support

Exclusion criteria

1. pre-existing sepsis 2. pre-existing chronic renal failure (dialysis dependent), liver failure other diseases precluding chance of survival.

Design outcomes

Primary

Measure	Time frame	Description
Mortality or multi-organ failure	7 days	Patients who survived for more than 7 days after ECMO treatment were defined as survival, and non-survival patients were defined as expired or multiple organ failure incompatible with life within 7 days after ECMO installation.

Countries

Taiwan

Outcome results